The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Disclosures: All authors declare to have no conflict of interest.

Contributions: Authorship: CD, MK, AK, HO designed the research, and MK, JB, CA, EW, AM and TaS and ToS performed the research, PG, WL, G B, NL, ER, HO contributed proteasome inhibitors and affinity based proteasome probes, SH analysed data, CD and AK wrote the paper. All authors state to have no conflicts of interest regarding the contents of this manuscript.